Shell Asset Management CO Xenon Pharmaceuticals Inc. Transaction History

Shell Asset Management CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 28, 2023	SELL	$34.84 - $43.54 $2,891 - $3,613	-83 Reduced 0.57%	14,515 $559,000
Q1 2023 May 15, 2023	SELL	$33.46 - $40.35 $1,706 - $2,057	-51 Reduced 0.35%	14,598 $522,000
Q4 2022 Feb 07, 2023	SELL	$33.06 - $39.43 $90,948 - $108,471	-2,751 Reduced 15.81%	14,649 $578,000
Q3 2022 Nov 14, 2022	SELL	$30.79 - $39.82 $142,403 - $184,167	-4,625 Reduced 21.0%	17,400 $628,000
Q2 2022 Aug 09, 2022	SELL	$25.44 - $35.16 $152 - $210	-6 Reduced 0.03%	22,025 $670,000
Q1 2022 May 04, 2022	SELL	$25.09 - $33.13 $82,746 - $109,262	-3,298 Reduced 13.02%	22,031 $673,000
Q4 2021 Feb 09, 2022	BUY	$15.6 - $35.4 $2,558 - $5,805	164 Added 0.65%	25,329 $791,000
Q3 2021 Nov 04, 2021	SELL	$14.86 - $19.45 $16,048 - $21,006	-1,080 Reduced 4.12%	25,165 $385,000
Q2 2021 Aug 12, 2021	BUY	$16.81 - $20.0 $24,206 - $28,800	1,440 Added 5.81%	26,245 $489,000
Q1 2021 May 10, 2021	BUY	$13.65 - $21.31 $338,588 - $528,594	24,805 New	24,805 $444,000

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.39B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

Stay updated on Shell Asset Management CO with notifications on news.